Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MolMed, a biotechnology company, has expanded the Phase III trial of its investigational anticancer drug NGR-hTNF in malignant pleural mesothelioma, in the US.
Subscribe to our email newsletter
NGR-hTNF is a vascular targeting agent belonging to peptide/cytokine complexes, which can selectively target the tumour vasculature.
The randomised, double-blind, placebo-controlled, multicentre Phase III NGR015 trial, will enroll 390 adult patients affected by malignant pleural mesothelioma with disease progressing after standard pemetrexed-based chemotherapy.
The primary endpoint is overall survival, while the secondary endpoints include progression-free survival, disease control rate, safety and patients’ quality of life.
The company expects to announce the results in 2013.